Taipei Exchange exchange. Sector: Healthcare. Industry: Medical Devices. Location Taiwan, Taipei.

Universal Vision Biotechnology Co., Ltd. [3218.TWOTaiwan

273USD5.5 (-2.01%)

• At close Thu Oct 06 2022

604,344,973 USD
MARKET CAP
41.877
PE
0.808
BETA (5y)
6.340
EPS

profit

1,127%

for 5 years

profit

909%

for 3 years

profit

217%

for 2 years

profit

19%

for 1 year

profit

2%

for this year

About Universal Vision Biotechnology Co., Ltd.

Universal Vision Biotechnology Co., Ltd. operates a chain of eye care clinics in Taiwan and China. Its clinics provide laser vision correction surgery for myopia, hyperopia, astigmatism, and presbyopia; intraocular lens surgery for presbyopia and cataract; phacoemulsification and femtosecond laser for cataract surgery; and myopia control services, as well as services for dry eyes, retinal detachment, macular degeneration, strabismus, amblyopia, and other eye diseases. The company also offers vision products and services, including a range of eyeglass frames, multifocal and progressive lenses for myopia and presbyopia, sunglasses, orthokeratology, rigid gas permeable lenses, regular/colored contact lenses, eye supplements, etc.; eye plastic and micro cosmetic surgery; and customized aesthetic medicine consulting. It operates 25 eye clinics and 34 optical stores in Taiwan; and 11 eye clinics and 11 optical stores in China. Universal Vision Biotechnology Co., Ltd. was founded in 1992 and is based in Taipei, Taiwan.

大學光學科技(股)公司係由一群致力於眼科生技視力光學工業的環境,自有的技術團隊在眼科醫療產業有多年經驗之專業眼科及眼視光學顧問公司。

Universal Vision Biotechnology Co., Ltd.
https://www.eyecenter.com.tw
© 2022 avazzy.com. All rights reserved
Make with 🤎 and ☕ for you!

Investing involves risk, including possible loss of principal.

The strategies discussed are strictly for illustrative and educational purposes and are not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. There is no guarantee that any strategies discussed will be effective.

International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation and the possibility of substantial volatility due to adverse political, economic or other developments. These risks often are heightened for investments in emerging/ developing markets or in concentrations of single countries.